Terms: = Gastric cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
554 results:
1. Lymph node metastases are more frequent in paediatric appendiceal NET ≥1.5 cm but without impact on outcome - Data from the German met studies.
Kuhlen M; Kunstreich M; Pape UF; Seitz G; Lessel L; Vokuhl C; Frühwald MC; Vorwerk P; Redlich A
Eur J Surg Oncol; 2024 Apr; 50(4):108051. PubMed ID: 38430702
[TBL] [Abstract] [Full Text] [Related]
2. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the
Sohn SH; Sul HJ; Kim BJ; Zang DY
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339049
[TBL] [Abstract] [Full Text] [Related]
4. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine.
He Z; Xu Y; Rao Z; Zhang Z; Zhou J; Zhou T; Wang H
Sci Total Environ; 2024 Feb; 912():169604. PubMed ID: 38157907
[TBL] [Abstract] [Full Text] [Related]
5. Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced gastric cancer (YCOG1601).
Sato S; Kunisaki C; Tamura Y; Yago A; Kasahara K; Sato T; Kondo H; Kosaka T; Akiyama H; Endo I
Anticancer Res; 2023 Dec; 43(12):5663-5670. PubMed ID: 38030195
[TBL] [Abstract] [Full Text] [Related]
6. Clinical significance of sarcopenia in patients undergoing treatment for gastric cancer.
Ozcan SGG; Kacan T; Kacmaz NK; Gundogan B; Vurgec IH; Ozyildirim S
Rev Assoc Med Bras (1992); 2023; 69(12):e20230568. PubMed ID: 37971119
[TBL] [Abstract] [Full Text] [Related]
7. Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for gastric cancer with Peritoneal metastasis.
Kobayashi D; Kodera Y; Fukushima R; Morita M; Fushida S; Yamashita N; Yoshikawa K; Ueda S; Yabusaki H; Kusumoto T; Arigami T; Hidemura A; Omori T; Yamaguchi H; Hirono Y; Tsuji Y; Moon JH; Tomita T; Imamura H; Nakanishi K; Shimizu D; Hirakawa A; Ishigami H; Kitayama J
Ann Surg Oncol; 2024 Feb; 31(2):735-743. PubMed ID: 37952018
[TBL] [Abstract] [Full Text] [Related]
8. A novel c-met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation.
An B; Nie W; Hu J; Fan Y; Nie H; Wang M; Zhao Y; Yao H; Ren Y; Zhang C; Wei M; Li W; Liu J; Yang C; Zhang Y; Li X; Tian G
Cell Death Dis; 2023 Nov; 14(11):728. PubMed ID: 37945598
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant Chemotherapy With S-1 Plus Docetaxel
Yamamoto M; Omori T; Shinno N; Hara H; Mukai Y; Sugase T; Takeoka T; Mikamori M; Kanemura T; Hasegawa S; Akita H; Haraguchi N; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H; Ohue M
Anticancer Res; 2023 Nov; 43(11):5015-5024. PubMed ID: 37909962
[TBL] [Abstract] [Full Text] [Related]
10. SMYD3 Modulates the HGF/met Signaling Pathway in gastric cancer.
De Marco K; Lepore Signorile M; Di Nicola E; Sanese P; Fasano C; Forte G; Disciglio V; Pantaleo A; Varchi G; Del Rio A; Grossi V; Simone C
Cells; 2023 Oct; 12(20):. PubMed ID: 37887325
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract] [Full Text] [Related]
12. Chemotherapy and Immune Checkpoint Blockade for gastric and Gastroesophageal Junction Adenocarcinoma.
Manji GA; Lee S; Del Portillo A; May M; Ana SS; Alouani E; Sender N; Negri T; Gautier K; Ge L; Fan W; Xie M; Sethi A; Schrope B; Tan AC; Park H; Oberstein PE; Shah MA; Raufi AG
JAMA Oncol; 2023 Dec; 9(12):1702-1707. PubMed ID: 37856106
[TBL] [Abstract] [Full Text] [Related]
13. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract] [Full Text] [Related]
14. The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-analysis.
Budginaite E; Kloft M; van Kuijk SMJ; Canao PA; Kooreman LFS; Pennings AJ; Magee DR; Woodruff HC; Grabsch HI
Gastric Cancer; 2023 Nov; 26(6):847-862. PubMed ID: 37776394
[TBL] [Abstract] [Full Text] [Related]
15. Systemic Therapy for Tumor Control in metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract] [Full Text] [Related]
16. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
17. Randomized controlled trial in gastric or gastroesophageal junction adenocarcinoma undergoing systemic therapy over two decades.
Xu BB; Lu J; Zheng HL; Xue Z; Zheng CH; Li P; Chen QY; Xie JW; Huang CM
Eur J Surg Oncol; 2023 Oct; 49(10):107007. PubMed ID: 37591026
[TBL] [Abstract] [Full Text] [Related]
18. Textbook Oncological Outcome in European GASTRODATA.
Sędłak K; Rawicz-Pruszyński K; Mlak R; Van Sandick J; Gisbertz S; Pera M; Dal Cero M; Baiocchi GL; Celotti A; Morgagni P; Vittimberga G; Hoelscher A; Moenig S; Kołodziejczyk P; Richter P; Gockel I; Piessen G; Da Costa PM; Davies A; Baker C; Allum W; Romario UF; De Pascale S; Rosati R; Reim D; Santos LL; D'ugo D; Wijnhoven B; Degiuli M; De Manzoni G; Kielan W; Frejlich E; Schneider P; Polkowski WP
Ann Surg; 2023 Nov; 278(5):823-831. PubMed ID: 37555342
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of Nationwide Trends in Nodal Sampling Guideline Adherence for gastric cancer: 2005-2017.
Mahenthiran AK; Logan CD; Janczewski LM; Valukas C; Warwar S; Silver CM; Feinglass J; Merkow RP; Bentrem DJ; Odell DD
J Surg Res; 2023 Nov; 291():514-526. PubMed ID: 37540969
[TBL] [Abstract] [Full Text] [Related]
20. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract] [Full Text] [Related]
[Next]
